Pan-human coronavirus and human bocavirus SYBR Green and TaqMan PCR assays; use in studying influenza A viruses co-infection and risk of hospitalization

E. A. Goka · P. J. Vallely · K. J. Mutton · P. E. Klapper

Introduction

Influenza A viruses are a significant cause of acute lower respiratory tract infections (ALRI), with 13.0 % of all children with influenza infection developing ALRI-equivalent to 20 million (95 % CI 13–32 million) ALRI cases per year [1]; and according to these authors, in 2008, between 28,000 and 111,500 children younger than 5 years died of influenza-associated ALRI. Among potential co-pathogens, human coronaviruses (hCoV) and human bocavirus (hBoV) are important emerging respiratory viruses [2, 3].

Coronaviruses infect a wide variety of hosts (animals and humans); Alphacoronaviruses and Betacoronaviruses infect mammals, whereas Gammacoronaviruses infect birds [4]. Most of the human coronaviruses (Alphacoronaviruses 229E and NL63 and Betacoronaviruses OC43, HKU1) cause mild influenza like illnesses, however in 2003, the severe acute respiratory syndrome (SARS)...
coronavirus caused a very severe form of respiratory disease in humans globally [5], resulting in over 900 deaths [6]. On 21 September 2012, a novel coronavirus was identified in lower respiratory tract of an adult male Qatari national in London [7]. Three months earlier (13 June 2012), Dutch researchers identified a similar virus in a Saudi Arabian national presenting with pneumonia [8–10]. As of 11 June 2014, 699 laboratory-confirmed cases of human infection with MERS-CoV have been reported to WHO, including at least 209 deaths [6].

Human bocavirus, was first discovered in respiratory specimens of patients with lower respiratory disease in 2005 by Allander et al. [11] using a random polymerase chain reaction (PCR)-cloning-sequencing protocol. Reviews by Schildgen et al. [3] and Zhenqiang et al. [12] showed that, since 2005, over 40 studies conducted globally identified human bocavirus in children with acute respiratory virus infections; and that most of these prevalence studies found hBoV occurring mainly together with other viruses. The significance of human bocaviruses in causing serious clinical disease is still under debate, with some studies finding that bocavirus may cause significant ALRI [3, 12], and others finding they only cause mild illness [3, 13, 14].

HBoV infection is reported to mainly occur as a co-infection with other respiratory viruses; some zoonotic hCoV have been associated with severe lower respiratory tract infection (LRTI). However these viruses are not, at present, routinely tested in clinical settings due to a lack of knowledge on the significance of these viruses in causing severe disease. Some recent studies have indicated that respiratory virus co-infections increases disease severity [15, 16], however the pattern of co-infection between influenza A viruses and hCoV and hBoV and their association with severe disease has not been clearly elucidated. We designed primers and optimized a real-time polymerase chain reaction (RT-PCR) assay for identification of 15 coronaviruses and used the RT-PCR targeting the NS1 region of the hBoV described by Qu et al. [17] to investigate the patterns of co-infections between influenza A virus with hCoV and hBoV and their association with severe clinical disease.

**Methodology**

Clinical samples and setting

We tested for hCoV and hBoV in 217 samples randomly selected from 596 influenza A viruses identified from 3,804 samples received between 24th June 2011 and 30th June 2012 at the Manchester Microbiology Partnership Laboratory (MMPL), a reference laboratory for the North West England serving a population of around 7 million people [18]. Influenza A viruses were identified using a well characterised in-house duplex real-time polymerase chain reaction assays and influenza A (H1N1) subtyped using the Public Health England (PHA) (H1)v) assay [19]. The PCRs were run on the ABI7500 real-time PCR instrument (Applied Biosystems, Warrington, United Kingdom). Samples were from patients aged between 1 and 98 years old (mean age 37.7, SD ± 30.4), seen as outpatients (at medical centres, clinics or hospitals), or admitted to a hospital in North West England.

Primers, templates and probes for hCoV, hBoV

To design primers for hCoV, complete genomic sequences for 15 coronavirus (Table 1), were downloaded from the GenBank (and details of their GenBank accession numbers available on request), aligned with BioEdit Sequence alignment Editor version 7.1.3.0 [20] and a consensus blasted using the BLAST program [GenBank, Bethesda MD, 20894 USA]; limiting the search to nucleotide collection (nt) database and organism Coronaviridae. One pair of primers targeting the region of the replicase open reading frame 1b (ORF1b) non-structural protein 15 (nsp15; XendoU/NendoU) uridylate specific endonuclease, which is highly conserved among all coronaviruses [21, 22] was selected; forward primer: 5′-TGGGGA GTAATGAACCGTA-3′ and reverse primer: 5′-ACATGT AAAAGAGCTAATAACAC-3′ (Eurofins MWG Operon, Table 1 Coronaviruses used in the design of pan-coronavirus primers (downloaded from GeneBank on 18th December, 2011)

| Coronavirus            | Number identified and downloaded |
|------------------------|----------------------------------|
| 1 Human coronavirus HKU1 | 20                               |
| 2 Human coronavirus NL63 | 2                                |
| 3 Human coronavirus OC43 | 4                                |
| 4 Human coronavirus 229E | 1                                |
| 5 Bovine coronavirus   | 12                               |
| 6 Porcine haemagglutinating virus | 2                   |
| 7 Murine hepatitis virus | 21                               |
| 8 Equine coronavirus   | 3                                |
| 9 Rat coronavirus      | 1                                |
| 10 Bat coronavirus     | 31                               |
| 11 Avian infectious bronchitis virus | 41          |
| 12 Canine coronavirus  | 1                                |
| 13 Sambar deer coronavirus | 1                     |
| 14 Bat SARS coronavirus | 10                               |
| 15 Duck coronavirus    | 1                                |
| Total                  | 151                              |
Germany); probe 5'-FAM-TTGTGTTAAAGATAGTGAG GTT-MGB -3' (Applied Biosystems, Warrington, UK).

The primer and template described by Qu et al. [17], GenBank accession no. NC_007455; forward primer 5'-TAATGACTGACAGACAGCTTAG-3', reverse primer 5'-TGTCGCCCAAGGATACT-3' (Eurofins MWG Operon, Ebersberg Germany); probe 5'-FAM-CTTCA- CCAATCCTGGTG-MGB-3' (Applied Biosystems, Warrington, UK), were used for identification of hBoV.

Determination of analytical sensitivity and reproducibility of RT-PCR protocols

To determine analytical sensitivity, synthetic DNA templates were constructed using sequence nt position 20062–20134 of Bovine coronavirus (accession number DQ811784.2 NCBI website): GGAGGATGAAGAGCCTTAATGCAACGGATTGGGTGG GGAGGATGAAGAGCCTTAATGCAACGGATTGGGTGG AACCTGCAAACTGTATCTGGCGGGACAGAC. These were inserted into a pEX-A plasmid vector (Eurofins MWG Operon, Ebersberg Germany) and propagated in Escherichia coli. For use in the coronavirus RT-PCR, the plasmid was linearized using BamHI restriction enzyme (New England BioLabs, Ipswich USA) and RNA transcribed using the T7 High Yield RNA synthesis Kit (New England BioLabs, Ipswich USA). Purified RNA or DNA was quantified using UV spectrophotometry and used to construct the standard curves used for quantitation in each of the PCR assays. To optimize the primer concentration, duplicate preparations of coronavirus 229E (obtained from Public Health England Type Culture Collection, Salisbury, UK), pEX-A RNA template, 20, 10, 7.50, 5 μM serial dilutions of forward and reverse primer and 10, 6.60, 3.3, 0.37 μM probe concentrations were set up in MicroAmp Fast Reaction PCR tubes and mounted on a 48 well plate. Similarly, for analytical sensitivity the hBoV PCR, 1:4 serial dilutions (in duplicates) of the pEX-A plasmid (Eurofins MWG Operon, Ebersberg Germany) were used in standard curve experiments.

PCR for identification of coronaviruses and bocavirus in samples

The Power SYBR Green RNA-to-CT 1-Step Kit (Applied Biosystems) was used in a one-step RT-PCR for detection of coronavirus, the reaction mixture comprised: 10 μl of Power SYBR Green RT-PCR Master Mix (2×), 2.5 μl forward and reverse primer (20 μM), 1 μl of Arrayscript RT Enzyme mix (125X), 2 μl of RNase free water and 3 μl of RNA template in positive control well or sample in test wells. For identification of bocavirus the Power SYBR Green PCR Master Mix (Applied Biosystems) was used: reaction mixture 10 μl of Power SYBR Green PCR Master Mix (2×), 2.5 μl forward and reverse primer (20 μM), 2 μl RNase free water and 3 μl of template in positive control well or sample in test wells. RT-PCR experiments were conducted on the StepOne and StepOne Plus Real Time PCR machine (Applied Biosystems) with cycling parameters for coronavirus of: 48 °C for 30 min, 95 °C for 10 min; followed by 40 cycles of denaturing at 95 °C for 15 s and 57 °C for 1 min; and a melting curve of 95 °C for 15 s, 57 °C for 15 s and 95 °C for 15 s. The bocavirus PCR used 95 °C for 10 min, 40 cycles of 95 °C for 15 s and 60 °C for 1 min and a melting curve of 95 °C for 15 s, 60 °C for 15 s and 95 °C for 15 s. The number of viral copies was calculated using the absolute quantification method published by Brankatschk et al. [23].

Confirmation of positive samples using MGB probes

Samples that were positive for coronavirus or bocavirus were confirmed with a TaqMan based RT-PCR. The probe concentrations were first optimized using duplicate preparations of 10, 6.6, 5, 3.3, 0.3 μM and 0.12 probe concentrations. Each well contained 10 μl of TaqMan Fast Universal PCR Master Mix (2X) (Applied Biosystems), 2.5 μl of probe, 2.5 μl forward and reverse primer, 2 μl of RNase free water and 3 μl of RNA template. The coronavirus PCR also contained the 1 μl Multiscribe Reverse Transcriptase (Applied Biosystems) and 1 μl of RNase inhibitor. The cycling conditions were; for coronavirus experiments: 50 °C for 2 min, 95 °C for 20 s, followed by 40 cycles of 95 °C for 1 s and 57 °C for 20 s; whereas for bocavirus: 95 °C for 20 s, followed by 40 cycles of 95 °C for 1 s and 60 °C for 20 s.

Polyacrylamide gel (PAGE) electrophoresis

Amplcons for coronavirus and bocavirus PCR were visualized using precast 8 % TBE polyacrylamide gel 1 mm 15 well (Applied Biosystems) run on an XCell SureLock™ Mini-Cell Electrophoresis chamber (Invitrogen Novex Mini cell), filled with 200 and 600 ml 1× BTE Running Buffer (Bioline, London) and loaded into the wells and the positive control well loaded with HyperLadder V (Bioline). The loaded XCell SureLock™ Mini-Cell chamber was run at 200 V, 18 mA for 35 min, stained with GelRed Nucleic Acid Stain (Biotium, Hayward, UK) for 30 min, and visualised under UV light on an Alphaimager 2200 machine (Alpha Innotech, San Leandro, Calif).
Statistical analysis

Two by two tables were drawn to describe the patterns of co-infection between influenza A virus, human coronavirus and human bocavirus and differences in distribution of single and dual infections by age, sex, and season. Differences were assessed using the Pearson’s Chi square ($\chi^2$) statistic, and for small samples, the Fisher’s exact test. Association between single and mixed virus infection and admission to a general ward (GW) or intensive care unit (ICU) were assessed using simple logistic regression models. All statistical analyses were performed with STATA software, version 11.0. (STATACorp, Texas 77845, USA).

Ethics

Ethical approval for the study was obtained from the National Health Service-Research Ethics Committee (NHS-REC), reference number 11/NW/0698), the University of Manchester Research Ethics Office. Research and Development R&D approval was obtained from the Central Manchester Universities Hospitals NHS Foundation Trust (reference number R01835) (Fig. 1)

Results

Efficiency, analytical sensitivity and reproducibility of the hCoV and hBoV PCRs

The optimum concentration for primers was 2.5 µl (20 µM) whereas the optimum concentration of the probe was 2.5 µl (6.6 µM). The optimum annealing temperature for the primers was 57 °C. At this temperature, the wells that contained coronavirus 229E and RNA template; gave the lowest threshold cycle (Ct value), (range 19–38), highest fluorescence signal (range 0.6–19.2), and the PCR product melted at 76.2 °C, which is within the Tm for coronaviruses PCR products (75.0 and 80.0 °C). Analytical sensitivity of the PCR assays was tested by seven 1:4 serial dilutions (10^4–100) for the hCoV and eleven serial dilution (10^6–10^0) for the hBoV. The hCoV assay was able to detect down to 2.6 copies/µl, whereas the hBoV was able to detect down to 4.9 copies/µl. Under optimum conditions, the duplicate samples gave reproducible results and the experiments were repeated three times giving a total number of 21 and 33 replicates. Our results compare well with previously published protocols of hCoV and hBoV. For example a SYBR Green RT-PCR assay for identification of hCoV, published in 2007, Escutenaair et al. [24] reported that their assay was able to detect down to 10 RNA copies/µl, whereas Vijgen et al. [25] pan-coronavirus assay (published in 2008) was far less sensitive with a lower detection limit of 5.0 x 10^3 RNA copies per microliter sample, Adach et al. [26] (1 and 10 genome copies). Further, hBoV assay by Neske et al. [27] was able to detect up to 3.8 x 10^6–3.8 x 10^3 copies/µl and Lu et al. [28] (10 copies). Our assays were therefore of good analytical sensitivity and could be used in diagnosis of hCoV. Polyacrylamide gel results indicated that the size of the PCR products obtained from the coronavirus 229E and bocavirus was similar to the coronavirus and bocavirus inserts into the pEX-A plasmid vector (a picture of the PAGE result for coronavirus is provided in Fig. 2).
Influenza A viruses co-infection with human coronavirus

Respiratory virus infections in samples that were positive for influenza A viruses

Of the 217 influenza A virus samples included in this study, the majority 95.4 % (207) were seasonal influenza A viruses and only 10 (4.6 %) were pandemic influenza A(H1N1)pdm09 infections. This was because the pandemic virus did not circulate in high numbers during the 2011/2012 season. The World Health Organisation (WHO) had declared the end of the pandemic on 10th August 2010 [29]. Human coronaviruses were found in 12 of the 217 samples whereas human bocavirus in 17 of the 217 samples. The Ct values for hCoV positive samples ranged from 21.95 to 35.0 (mean 31.3) corresponding to 122 and 75 copies/µl respectively, whereas for hBoV it ranged from 26.95 to 36.0 with (mean of 32.75) corresponding to 123 and 92 copies/µl, indicating low viral loads. Previous studies have also reported finding hBoV low and not high viral loads Zhenqiang et al. [12].

The same samples used for identification of hCoV and hBoV were also previously tested for other respiratory virus infections: influenza B virus (Flu B), respiratory syncytial virus (RSV), rhinoviruses (RV), adenovirus (AdV), human metapneumovirus (hMPV), and human parainfluenza virus types 1–3 (hPIV1-3). When the results of other respiratory viruses are included, 149 (72.0 %) of the 207 seasonal influenza A viruses were single infections, and more than one virus was detected in 58 (28.0 %) cases. Only 1 of the 10 patients with pandemic influenza A(H1N1)pdm09 virus infection was also infected with human coronavirus and rhinovirus. Of the 34 co-infections between seasonal influenza A and other respiratory viruses; 19 cases were infected with hMPV, 14 with RV, 2 with Flu B, 2 with RSV, and 2 with hPIV3 virus.

Demographic and other characteristics of single and dual infections

The age, sex, and season distribution of patients are given in (Table 2). The majority of seasonal influenza A single infections and hCoV and hBoV co-infections were in adults >19 years old. Specifically, 104/149 (69.8 %) of single seasonal influenza A virus infections were in adults >19 years compared to 8/11 (72.7 %) of SeasFluA/hCoV co-infections and 9/13 (69.2 %) of SeasFluA/hBoV co-infections in adults >19 years old (and these differences were not statistically significant)-Table 2. However co-infections between Flu A and other respiratory viruses were significantly higher among children <5 years old (11.2 %–14/34; p = 0.03). Regarding seasonal distribution, most of both single and dual virus infections occurred during the winter season (with summer season having low virus activity). This is probably because we tested for hCoV and hBoV in samples that were positive for influenza A viruses and influenza viruses are known to circulate in high numbers mainly in winter seasons.

A larger percentage (61.5 %; 8/13) of SeasFluA/hBoV co-infections were identified in patients that were admitted to either a general ward (GW) or the intensive care unit (ICU) compared to 44.3 % (66/149) of single SeasFlu A virus infections (OR 2.5 95 % CI 0.67–9.34, p = 0.17). In a stratified analysis, there was a trend towards higher association between Flu A, hCoV and hBoV with increasing age, but none of these were statistically significant (Table 2). In children ≤5 years, 50 % (1/2) of SeasFluA/hCoV and 66.7 % (2/3) of SeasFluA/hBoV co-infections were admitted to a GW or ICU compared to 26.5 % (9/34) of single influenza A virus infections. Comparatively, among patients aged 24–45 years old, 66.7 % (2/3) with SeasFluA/hCoV co-infection were admitted either to a GW/ICU compared to 56.3 % (18/32) of those with single seasonal influenza A virus infections (OR 2.20, 95 % CI 0.46–10.35, p = 0.32), and 100 % (3/3) of SeasFluA/hBoV co-infections were admitted to a GW/ICU. Similarly among those aged >65 years old, 75.0 % (3/4) of those with SeasFluA/hBoV co-infection were admitted to GW/ICU compared to 60.0 % (27/45) with single seasonal influenza A virus infections (OR 6.0, 95 % CI 0.46–76.54, p = 0.17) and 100 % (1/1) of SeasFluA/hCoV co-infection.

Fig. 2 Polyacrylamide gel electrophoresis of hCoV PCR products. PCR products from two experiments, one where each well contained 3 µl of hCoV229E RNA (Exp1) and another 5 µl, to increase yield (Exp2) and products from RNA produced from the pEX-A vector. HyperLadder V marks are from bottom, 25, 50, 75, 100 bp up to 500. The marks at 50 bp are due to primer dimmers which are known to form in SYBR Green PCRs.
was admitted to a GW/ICU (Table 2). The lack of statistical significance was probably because most of the cells in the >5–19, >19–24 and >45–65 years age groups had zero observations; when these age groups were eliminated from the analysis, SeasFluA/hBoV co-infections was associated with a significant increase in risk of admission to GW/ICU (OR: 5.83, 95 % CI: 1.03–32.93, \( p = 0.05 \)).

### Discussion and conclusion

The importance of developing a coronavirus RT-PCR assay that is able to identify both *Alphacoronaviruses* and *Betacoronaviruses* which attack animals and humans, and *Gammacoronaviruses* which attack birds, is that such assays could identify zoonotic coronaviruses associated with more severe disease in humans [2, 5, 30, 31]. Therefore the clinical usability of any PCR assay for the identification of all or most coronaviruses depends on its ability to amplify a region which is common to all coronaviruses (both human and human adapted animal viruses), and its sensitivity. The primers for coronavirus we designed target the replicase ORF1b nsp15 (XendoU/NendoU) uridylate specific endonuclease gene, which is highly conserved among all coronaviruses [21, 22] and we confirmed our results with a TaqMan probe. The quality of primers depends, among others, on their ability not to give nonspecific amplifications. Our primers for identification of coronaviruses did not give nonspecific amplifications as indicated by the melting curves. In addition, the hCoV standard curve experiments indicated that the hCoV RT-PCR assay was able to pick up to 2 copies/µl of human coronavirus RNA template, our assays results compare equally with those of a previously published SYBR green assay for coronaviruses [24–26]. We are therefore confident that it could be applied for diagnosis of coronaviruses in clinical settings subject to further experiments in statistically significant number of samples.

Some studies have reported that co-infections are predominantly in younger and older patients [32–34]. In this study, single seasonal influenza A viruses were predominantly in adults >18 years old in agreement with our earlier published study [35]. Similarly a higher proportion of hCoV and hBoV co-infections were in adults 18 to 65 years old. This suggests high prevalence of hCoVs and hBoV among older patients. Comparatively the majority of other respiratory virus co-infections (RSV, RV, hMPV and hPIV1-3) were in children ≤5 years old (Table 2). Regarding seasonality of the viruses, almost all the respiratory virus single and dual infections in this study were identified in the winter season. This could be because we tested other respiratory virus co-infections (RSV, RV, hMPV and hPIV1-3) were in children ≤5 years old (Table 2). Regarding seasonality of the viruses, almost all the respiratory virus single and dual infections in this study were identified in the winter season. This could be because we tested

---

**Table 2** Demographics and disease severity in single, dual and multiple seasonal influenza A virus infections

| Variable | SeasFlu A only | SeasFlu A + hCoV | SeasFlu A + hBoV | SeasFlu A + other RVIs |
|----------|---------------|-----------------|-----------------|-----------------------|
| Age (years)—n (%) | | | | |
| \( \leq 5 \) | 34 (22.8) | 2 (18.2) | 3 (23.1) | 14 (41.2)* |
| 5–19 | 11 (7.4) | 1 (9.1) | 1 (7.7) | 2 (5.9) |
| 19–24 | 6 (4.0) | 0 (0.0) | 0 (0.0) | 2 (5.9) |
| 24–45 | 32 (21.5) | 3 (27.3) | 3 (23.1) | 7 (20.6) |
| 45–65 | 21 (14.1) | 4 (36.4) | 2 (15.4) | 4 (11.8) |
| >65 | 45 (30.2) | 1 (9.1) | 4 (30.8) | 5 (14.7) |
| Total | 149 (100) | 11 (100) | 13 (100) | 34 (100) |
| Male sex | 68 (49.3) | 7 (63.6) | 6 (46.2) | 17 (50.0) |

| General ward/ICU—n (%) | | | | |
| Age ≤5 | 9/34 (26.5) | 1/2 (50.0) | 2/3 (66.7) | 3/14 (21.43) |
| >5 ≤19 | 0/0 (0.0) | 0/0 (0.0) | 0/0 (0.0) | 0/0 (0.0) |
| >19 ≤24 | 1/6 (16.7) | 0/0 (0.0) | 0/0 (0.0) | 0/2 (0.0) |
| >24 ≤45 | 18/32 (56.3) | 2/3 (66.7) | 3/3 (100) | 4/7 (57.1) |
| >45 ≤65 | 11/21 (52.4) | 0/4 (0.0) | 0/2 (0.0) | 2/4 (50.0) |
| >65 | 27/45 (60.0) | 1/1 (100) | 3/4 (75.0) | 3/5 (60.0) |
| Total | 66/149 (44.3) | 4/11 (36.6) | 8/13 (61.5) | 12/34 (35.3) |

| OR (95 % CI; \( p \) value) | Baseline | 0.60 (0.15–2.40; 0.47) | 2.5 (0.67–9.34; 0.17) | 0.87 (0.37–2.10; 0.76) |

* SeasFlu A seasonal influenza A virus, hCoV human coronavirus, hBoV human bocavirus, other RVIs co-infection between seasonal influenza A and other respiratory viruses (viruses involved; hBoV = 4, rhinovirus = 14, influenza B = 2, respiratory syncytial virus = 2, adenovirus = 4, human metapneumovirus = 19 and parainfluenza virus type 3 = 1)

* The statistic was significant at \( p \leq 0.05 \)

* Odds ratios were adjusted for age group and sex
for hCoV and hBoV in samples that were positive for influenza A viruses and influenza viruses are known to circulate mainly during winter season. Our findings are in agreement with other studies [16, 36], which also reported dual or multiple respiratory virus infections mainly occur during winter season.

This study did not find a significant association between seasonal influenza A viruses co-infection with hCoV and hBoV and severe disease. Given the high co-infection rates with other respiratory viruses, and also it is mostly identified in low copy numbers. However, the results of this study indicate a trend towards the hypothesis that hBoV co-infection might promote hospitalization especially among patients >65 years old and ≥24 ≤45 years old. Further, a number of other factors; age, comorbidities, immune status, and bacterial co-infection, affect disease outcome [37–39]. However in this study we did not control for these factors as the datum did not have these variables. This may have affected our outcomes and this should be born in mind when interpreting our results.

In conclusion, our RT-PCR protocol for the identification of coronaviruses is sensitive, specific and reliable and could be used for diagnosis of coronaviruses. More and larger studies are needed to confirm the role of hBoV in causing severe disease when they co-infect with influenza A viruses.

Acknowledgments The authors would like to acknowledge the University of Manchester, the Manchester Academic Health Science Centre, and the Central Manchester University Hospitals NHS Foundation Trust and staff for their support in this research. This work was received financial and institutional support from the University of Manchester.

Conflict of interest All authors no conflict of interest.

References

1. Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet. 2011;378:1917–30.
2. Masters PS. The molecular biology of coronaviruses. Adv Virus Res. 2006;66:193–292.
3. Schildgen O, Muller A, Allander T, Mackay IM, Volz S, Kupfer B, Simon A. Human bocavirus: passenger or pathogen in acute respiratory tract infections? Clin Microbiol Rev. 2008;21:291–304.
4. Lai MMC, Perlan S, Anderson LJ. Coronavirusidae. In: Knipe DM, Griffin DE, Lamb RA, Straus SE, Howley PM, Martin MA, Roizman B, editors. Fields virology. Philadelphia: Lippincott Williams and Wilkins; 2007. p. 1305–35.
5. Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev. 2005;69:635–64.
6. World Health Organisation (WHO). Middle East respiratory syndrome coronavirus (MERS-CoV) summary and literature update as of 11 June 2014. http://www.who.int/csr/disease/coronavirus_infections/archive_updates/en/. Accessed 5 Nov 2014.
7. Public Health England (PHA). Acute respiratory illness associated with a new virus identified in the UK. London:PHA; 2012 (Press release) 2012.
8. Promed email. Novel coronavirus-Saudi Arabia: human isolate archive number. Archive number: 20120920.1302733. (2012) 20 Sept 2012.
9. Zaki AM, van BS, Besteboer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–20.
10. Bermingham A, Chand MA, Brown GS, Aarons E, Tong C, Langrish C, et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill. 2012;17:20290.
11. Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci USA. 2005;102:12891–6.
12. Zhengiang BA, Formenty PBH, Roth CE. Human bocavirus, a real respiratory tract pathogen. Afr J Microbiol Res. 2007;1:51–6.
13. Lusebrink J, Wittleben F, Schildgen V, Schildgen O, Schildgen V, Schildgen O. Human bocavirus-insights into a newly identified respiratory virus. Viruses. 2009;1:3–12.
14. Wright PF, Neuman G, Kawaoka Y. Orthomyxoviruses. In: Knipe DM, Griffin DE, Lamb RA, Straus SE, Howley PM, Martin MA, Roizman B, editors. Fields virology. Philadelphia: Lippincott Williams and Wilkins; 2007. p. 1690–789.
15. Richard N, Komurian-Pradel F, Javouhey E, Perret M, Rajoharian S, Bagnaud A, et al. The impact of dual viral infection in infants admitted to a pediatric intensive care unit associated with severe bronchiolitis. Pediatr Infect Dis J. 2008;27:213–7.
16. Drews AL, Atmar RL, Glezen WP, Baxter BD, Frieda PA, Greenberg SB. Dual respiratory virus infections. Clin Infect Dis. 1997;25:1421–9.
17. Qu XW, Duan ZJ, Qi YZ, Xie ZP, Gao HC, Liu WP, et al. Human bocavirus infection, People’s Republic of China. Emerg Infect Dis. 2007;13:165–8.
18. Office of National Statistics (ONS). 2011 Census: Usual resident population by five-year age group, local authorities in the United Kingdom; Office for National Statistics, UK, 2012. http://www.ons.gov.uk/ons/rel/census/2011-census/population-and-household-estimates-for-the-united-kingdom/stb-2011-census-population-estimates-for-the-united-kingdom.html. Accessed 28 Dec 2012.
19. Ellis J, Iturriza M, Allen R, Bermingham A, Brown K, Gray J, Brown D. Evaluation of four real-time PCR assays for detection of influenza A(H1N1)v viruses. Euro Surveill 2009;14.
20. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser. 1999;41:95–8.
21. Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, et al. The Genome sequence of the SARS-associated coronavirus. Science. 2003;300:1399–404.
22. Ivanov KA, Hertzig T, Rozanov M, Bayer S, Thiel V, Gorbalenya AE, Ziebuhr J. Major genetic marker of nidoviruses encodes a replicative endoribonuclease. Proc Natl Acad Sci USA. 2004;101:12694–9.
23. Brankatschk R, Bodenhausen N, Zeyer J, Burgmann H. Simple absolute quantification method correcting for quantitative PCR efficiency variations for microbial community samples. Appl Environ Microbiol. 2012;78:4481–9.

24. Escutenaire S, Mohamed N, Isaksson M, Thoren P, Klingeborn B, Belak S, et al. SYBR Green real-time reverse transcription-polymerase chain reaction assay for the generic detection of coronaviruses. Arch Virol. 2007;152:41–58.

25. Vijgen L, Moes E, Keyaerts E, Li S, Van RM. A pancoronavirus RT-PCR assay for detection of all known coronaviruses. Methods Mol Biol. 2008;454:3–12. doi:10.1007/978-1-59745-181-9_1:3-12.

26. Adachi D, Johnson G, Draker R, Ayers M, Mazzulli T, Talbot PJ, Tellier R. Comprehensive detection and identification of human coronaviruses, including the SARS-associated coronavirus, with a single RT-PCR assay. J Virol Methods. 2004;122:29–36.

27. Neske F, Blessing K, Tollmann F, Schubert J, Rethwilm A, Kreth HW, Weissbrich B. Real-time PCR for diagnosis of human bocavirus infections and phylogenetic analysis. J Clin Microbiol. 2007;45:2116–22.

28. Lu X, Chittaganpitch M, Olsen SJ, Mackay IM, Sloots TP, Fry AM, Erdman DD. Real-time PCR assays for detection of bocavirus in human specimens. J Clin Microbiol. 2006;44:3231–5.

29. World Health Organisation (WHO): H1N1 in post-pandemic period; 2010. http://www.who.int/mediacentre/news/statements/2010/h1n1_vpc_20100810/en/. Accessed 9 Nov 2011.

30. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361:1319–25.

31. Guan Y, Peiris JS, Zheng B, Poon LL, Chan KH, Zeng FY, et al. Molecular epidemiology of the novel coronavirus that causes severe acute respiratory syndrome. Lancet. 2004;363:99–104.

32. Echenique IA, Chan PA, Chapin KC, Andrea SB, Fava JL, Mermel LA. Clinical characteristics and outcomes in hospitalized patients with respiratory viral co-infection during the 2009 H1N1 influenza pandemic. PLoS One. 2013;8:e60845.

33. Razanajatovo NH, Richard V, Hoffmann J, Reynolds JM, Razafitrimo GM, Randremana RV, Heraud JM. Viral etiology of influenza-like illnesses in Antananarivo, Madagascar, July 2008–June 2009. PLoS One. 2011;6:e17579.

34. Peci A, Winter AL, Gubbay JB, Skowronska DM, Balogun EI, De LC, et al. Community-acquired respiratory viruses and co-infection among patients of Ontario sentinel practices, April 2009 to February 2010. Influenza Other Respir Viruses. 2013;7:559–66.

35. Goka E, Vaillencourt P, Mutton K, Klaasen F, Influenza A, viruses dual and multiple infections with other respiratory viruses and risk of hospitalisation and mortality. Influenza Other Respir Viruses. 2013;7:1079–87.

36. Tanner H, Boxall E, Osman H. Respiratory viral infections during the 2009-2010 winter season in Central England, UK: incidence and patterns of multiple virus co-infections. Eur J Clin Microbiol Infect Dis. 2012;31:3001–6.

37. Van Kerkhove MD, Vandemaële KA, Shinde V, Jaramillo-Gutierrez G, Koukounari A, Donnelly CA, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med. 2011;8:e1001053.

38. Jackson S, Mathews KH, Pulanic D, Falconer R, Rudan I, Campbell H, Nair H. Risk factors for severe acute lower respiratory infections in children: a systematic review and meta-analysis. Croat Med J. 2013;54:110–21.

39. Alvarez AE, Marson FA, Bertuzzo CS, Arns CW, Ribeiro JD. Epidemiological and genetic characteristics associated with the severity of acute viral bronchiolitis by respiratory syncytial virus. J Pediatr (Rio J). 2013;89:531–43.